Adverse events287

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 287

Download this page as JSON

Type	Event	Organ system	Group	Affected	At risk	Events
other	Constipation	Gastrointestinal disorders	Double Blind Period: Placebo	6	167	6
other	Constipation	Gastrointestinal disorders	Double Blind Period: TV-44749 318 mg	4	163	4
other	Constipation	Gastrointestinal disorders	Double Blind Period: TV-44749 425 mg	8	168	8
other	Constipation	Gastrointestinal disorders	Double Blind Period: TV-44749 531 mg	8	169	10
other	Constipation	Gastrointestinal disorders	Integrated Study Period: TV-44749 318 mg	7	204	7
other	Constipation	Gastrointestinal disorders	Integrated Study Period: TV-44749 425 mg	12	203	12
other	Constipation	Gastrointestinal disorders	Integrated Study Period: TV-44749 531 mg	9	197	11
other	Injection site erythema	General disorders	Double Blind Period: Placebo	1	167	1
other	Injection site erythema	General disorders	Double Blind Period: TV-44749 318 mg	12	163	14
other	Injection site erythema	General disorders	Double Blind Period: TV-44749 425 mg	21	168	25
other	Injection site erythema	General disorders	Double Blind Period: TV-44749 531 mg	15	169	18
other	Injection site erythema	General disorders	Integrated Study Period: TV-44749 318 mg	15	204	19
other	Injection site erythema	General disorders	Integrated Study Period: TV-44749 425 mg	24	203	28
other	Injection site erythema	General disorders	Integrated Study Period: TV-44749 531 mg	22	197	27
other	Injection site induration	General disorders	Double Blind Period: Placebo	4	167	6
other	Injection site induration	General disorders	Double Blind Period: TV-44749 318 mg	18	163	23
other	Injection site induration	General disorders	Double Blind Period: TV-44749 425 mg	23	168	29
other	Injection site induration	General disorders	Double Blind Period: TV-44749 531 mg	23	169	36
other	Injection site induration	General disorders	Integrated Study Period: TV-44749 318 mg	20	204	30
other	Injection site induration	General disorders	Integrated Study Period: TV-44749 425 mg	27	203	35

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNone stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05693935/events

API reference For AI assistants

Adverse events287

Sources 3

Read this list from software.